Bioinformatics analysis of an immunotherapy responsiveness-related gene signature in predicting lung adenocarcinoma prognosis.

ABSTRACT:

Background

Immune therapy has become first-line treatment option for patients with lung cancer, but some patients respond poorly to immune therapy, especially among patients with lung adenocarcinoma (LUAD). Novel tools are needed to screen potential responders to immune therapy in LUAD patients, to better predict the prognosis and guide clinical decision-making. Although many efforts have been made to predict the responsiveness of LUAD patients, the results were limited. During the era of immunotherapy, this study attempts to construct a novel prognostic model for LUAD by utilizing differentially expressed genes (DEGs) among patients with differential immune therapy responses.

Methods

Transcriptome data of 598 patients with LUAD were downloaded from The Cancer Genome Atlas (

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC11225057 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature